Karen L. Smith Insider Trading $XLRN ACCELERON PHARMA INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Karen L. Smith.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Karen L. Smith. Karen L. Smith is Director in ANTARES PHARMA, INC. ($ATRS) and Director in SANGAMO THERAPEUTICS, INC ($SGMO) and EVP, R&D and CMO in Jazz Pharmaceuticals plc ($JAZZ) and Global Head of R&D and CMO in Jazz Pharmaceuticals plc ($JAZZ) and Director in ACCELERON PHARMA INC ($XLRN) and Director in Sucampo Pharmaceuticals, Inc. ($SCMP) and EVP, Chief Medical Officer in Emergent BioSolutions Inc. ($EBS).
Karen L. Smith in ACCELERON PHARMA INC
Trading Symbol: XLRNIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Karen L. Smith: Director
Holdings: 9,561 shares
Current Value: $226,978
Latest Transaction: Apr 05 2021
$XLRN Market Capitalization: $879.48M
$XLRN Previous Close: $23.74
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Karen L. Smith in ACCELERON PHARMA INC
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, XLRN, ATRS, EBS, JAZZ, SGMO, SCMP
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 52.99 | 2,050 | 108,630 | 4,085 | |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 41.64 | 1,875 | 78,075 | 3,750 | |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 35.34 | 5,000 | 176,700 | 10,000 | |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 141.15 | 641 | 90,477 | 1,622 | 2.3 K to 1.6 K (-28.33 %) |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 140.13 | 11,223 | 1,572,679 | 2,263 | 13.5 K to 2.3 K (-83.22 %) |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 52.99 | 2,050 | 108,630 | 13,486 | 11.4 K to 13.5 K (+17.93 %) |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 41.64 | 1,875 | 78,075 | 11,436 | 9.6 K to 11.4 K (+19.61 %) |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 35.34 | 5,000 | 176,700 | 9,561 | 4.6 K to 9.6 K (+109.63 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 52.99 | 2,050 | 108,630 | 6,135 | |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 41.64 | 1,875 | 78,075 | 5,625 | |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 35.34 | 5,000 | 176,700 | 15,000 | |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 137.92 | 941 | 129,783 | 4,561 | 5.5 K to 4.6 K (-17.10 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 136.92 | 3,796 | 519,748 | 5,502 | 9.3 K to 5.5 K (-40.83 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 136.22 | 2,987 | 406,889 | 9,298 | 12.3 K to 9.3 K (-24.31 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 134.54 | 1,201 | 161,583 | 12,285 | 13.5 K to 12.3 K (-8.91 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 52.99 | 2,050 | 108,630 | 13,486 | 11.4 K to 13.5 K (+17.93 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 41.64 | 1,875 | 78,075 | 11,436 | 9.6 K to 11.4 K (+19.61 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 35.34 | 5,000 | 176,700 | 9,561 | 4.6 K to 9.6 K (+109.63 %) |
Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 1,622 | 0 | 4,561 | 2.9 K to 4.6 K (+55.19 %) |
Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 52.99 | 8,185 | 433,723 | 8,185 | |
Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 1,377 | 0 | 2,939 | 1.6 K to 2.9 K (+88.16 %) |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 41.64 | 7,500 | 312,300 | 7,500 | |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 1,250 | 0 | 1,562 | 312 to 1.6 K (+400.64 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 40.61 | 1,875 | 76,144 | 1,875 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 312 | 0 | 312 | 0 to 312 |
Nov 15 2017 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 35.34 | 20,000 | 706,800 | 20,000 |
Page: 1